Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 12/20 | 0.48 |
| ▸ | IKZF1 | Q13422 | 5/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | IL1B | P01584 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.42 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30819811 | 1.00 | IKZF2 (0.61) | IKZF2CRBNIKZF1IKZF3BRD4 | |
| Trifluoroacetic Acid SCHEMBL30819813 | 0.94 | IKZF2 (0.57) | IKZF2CRBNIKZF1IKZF3BRD4 | |
| SCHEMBL30819850 | 0.86 | IKZF2 (0.47) | IKZF2CRBNIKZF1IKZF3BRD4 | |
| SCHEMBL27241639 | 0.86 | IKZF2 (0.47) | IKZF2CRBNIKZF1IKZF3BRD4 | |
| SCHEMBL30819859 | 0.86 | IKZF2 (0.47) | IKZF2CRBNIKZF1IKZF3BRD4 | |
| SCHEMBL24321718 | 0.85 | IKZF2 (0.68) | IKZF2CRBNIKZF1IKZF3BRD4 | |
| Hydrochloric Acid SCHEMBL22345861 | 0.84 | IKZF2 (0.67) | IKZF2CRBNIKZF1IKZF3BRD4 | |
| SCHEMBL30798405 | 0.81 | IKZF2 (0.59) | IKZF2CRBNIKZF1IKZF3BRD4 | |
| SCHEMBL27092914 | 0.81 | IKZF2 (0.59) | IKZF2CRBNIKZF1IKZF3BRD4 | |
| SCHEMBL27092921 | 0.81 | IKZF2 (0.59) | IKZF2CRBNIKZF1IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190841-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2024086759-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190841-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | IKZF2 21/4885CRBN 47/4885IKZF1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.